Datopotamab Deruxtecan Improves Survival Over Chemotherapy in Patients with Previously Untreated, Locally Recurrent Inoperable or Metastatic TNBC By Ogkologos - April 28, 2026 161 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TROPION-Breast02 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR New on NCI’s Websites for April 2024 April 12, 2024 A Poet’s Autobiography of Cancer May 31, 2023 Tumors With KRAS G12C Mutation Respond to Adagrasib and Using Toripalimab... April 19, 2023 EMA Recommends Extension of Therapeutic Indications for Durvalumab November 18, 2022 Load more HOT NEWS Meet Rosalie: St. Jude Children’s Research Hospital’s New Service Dog For... Coming Full Circle on Cancer and Extrachromosomal DNA Encorafenib, Cetuximab Combination Approved for Metastatic Colorectal Cancer Treatment with Nivolumab and Low-Dose Ipilimumab is Effective and Tolerable in...
